{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:59:08Z","timestamp":1788994748619,"version":"build-2803163510"},"reference-count":57,"publisher":"Japan Atherosclerosis Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2024,12,1]]},"DOI":"10.5551\/jat.64767","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T18:13:07Z","timestamp":1718215987000},"page":"1733-1747","source":"Crossref","is-referenced-by-count":19,"title":["Cardiovascular Adverse Events Associated with Tumor Necrosis Factor-Alpha Inhibitors: A Real-World Pharmacovigilance Analysis"],"prefix":"10.5551","volume":"31","author":[{"given":"Junlong","family":"Ma","sequence":"first","affiliation":[{"name":"Center of Clinical Pharmacology, Th ird Xiangya Hospital, Central South University"},{"name":"Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangfan","family":"Cai","sequence":"additional","affiliation":[{"name":"Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Hospital of Changsha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeying","family":"Feng","sequence":"additional","affiliation":[{"name":"Center of Clinical Pharmacology, Th ird Xiangya Hospital, Central South University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[{"name":"Center of Clinical Pharmacology, Th ird Xiangya Hospital, Central South University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ and Gabriel SE: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum, 2005; 52: 402-411","DOI":"10.1002\/art.20853"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, Canning C and Schneeweiss S: Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis, 2006; 65: 1608-1612","DOI":"10.1136\/ard.2005.050377"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ and Lacaille D: Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis, 2012; 71: 1524-1529","DOI":"10.1136\/annrheumdis-2011-200726"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Schieir O, Tosevski C, Glazier RH, Hogg-Johnson S and Badley EM: Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann Rheum Dis, 2017; 76: 1396-1404","DOI":"10.1136\/annrheumdis-2016-210275"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O\u2019Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS and McAlindon T: 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol, 2016; 68: 1-26","DOI":"10.1002\/art.39480"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Hu S, Lin C, Cai X, Zhu X, Lv F, Nie L and Ji L: The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis. Mediators Inflamm, 2021; 2021: 7712587","DOI":"10.1155\/2021\/7712587"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Bili A, Tang X, Pranesh S, Bozaite R, Morris SJ, Antohe JL, Kirchner HL and Wasko MC: Tumor necrosis factor alpha inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res (Hoboken), 2014; 66: 355-363","DOI":"10.1002\/acr.22166"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Nasir A, Setoguchi S, Solomon DH and Investigators C: Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis, 2011; 70: 576-582","DOI":"10.1136\/ard.2010.129916"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Lecour S, Smith RM, Woodward B, Opie LH, Rochette L and Sack MN: Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol, 2002; 34: 509-518","DOI":"10.1006\/jmcc.2002.1533"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Skeoch S and Bruce IN: Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol, 2015; 11: 390-400","DOI":"10.1038\/nrrheum.2015.40"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Aderka D, Engelmann H, Maor Y, Brakebusch C and Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med, 1992; 175: 323-329","DOI":"10.1084\/jem.175.2.323"},{"key":"12","unstructured":"12) Global market report of TNF-\u03b1 inhibitors.: ReportLinker; [28 Feb 2023]. Available from: https:\/\/www.reportlinker.com\/p06241875\/TNF-Alpha-Inhibitors-Global-Market-Report.html?utm_source=GNW"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Choy EH and Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med, 2001; 344: 907-916","DOI":"10.1056\/NEJM200103223441207"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Levin AD, Wildenberg ME and van den Brink GR: Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohns Colitis, 2016; 10: 989-997","DOI":"10.1093\/ecco-jcc\/jjw053"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kinzer JL, Halseth TA, Kang J, Kim SY, Kumaran P, Ford M, Saveliev S, Skilton SJ and Schwendeman A: Physicochemical characterization and functionality comparison of Humira(R)(adalimumab), Remicade(R)(infliximab) and Simponi Aria(R)(golimumab). Int J Pharm, 2023; 635: 122646","DOI":"10.1016\/j.ijpharm.2023.122646"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Leone GM, Mangano K, Petralia MC, Nicoletti F and Fagone P: Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. J Clin Med, 2023; 12:","DOI":"10.3390\/jcm12041630"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Jiao XF, Li HL, Jiao XY, Guo YC, Zhang C, Yang CS, Zeng LN, Bo ZY, Chen Z, Song HB and Zhang LL: Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System. Sci Rep, 2020; 10: 11955","DOI":"10.1038\/s41598-020-68906-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Lancellotti P, Suter TM, Lopez-Fernandez T, Galderisi M, Lyon AR, Van der Meer P, Cohen Solal A, Zamorano JL, Jerusalem G, Moonen M, Aboyans V, Bax JJ and Asteggiano R: Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J, 2019; 40: 1756-1763","DOI":"10.1093\/eurheartj\/ehy453"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Tregunno PM, Fink DB, Fernandez-Fernandez C, Lazaro-Bengoa E and Noren GN: Performance of probabilistic method to detect duplicate individual case safety reports. Drug Saf, 2014; 37: 249-258","DOI":"10.1007\/s40264-014-0146-y"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Dong Z, Ye X, Chen C, Wang R, Liu D, Xu X, Zhou X and He J: Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration\u2019s Adverse Event Reporting System. Br J Clin Pharmacol, 2022; 88: 4180-4190","DOI":"10.1111\/bcp.15361"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Hu Y, Gong J, Zhang L, Li X, Li X, Zhao B and Hai X: Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol, 2020; 84: 106601","DOI":"10.1016\/j.intimp.2020.106601"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Rothman KJ, Lanes S and Sacks ST: The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf, 2004; 13: 519-523","DOI":"10.1002\/pds.1001"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A and De Freitas RM: A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol, 1998; 54: 315-321","DOI":"10.1007\/s002280050466"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Wang T, Zhao Z, Yu X, Zeng T, Xu M, Xu Y, Hu R, Chen G, Su Q, Mu Y, Chen L, Tang X, Yan L, Qin G, Wan Q, Gao Z, Wang G, Shen F, Luo Z, Qin Y, Chen L, Huo Y, Li Q, Ye Z, Zhang Y, Liu C, Wang Y, Wu S, Yang T, Deng H, Zhao J, Xu Y, Li M, Chen Y, Wang S, Ning G, Bi Y, Shi L, Lu J and Wang W: Age-specific modifiable risk factor profiles for cardiovascular disease and all-cause mortality: a nationwide, population-based, prospective cohort study. Lancet Reg Health West Pac, 2021; 17: 100277","DOI":"10.1016\/j.lanwpc.2021.100277"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Aniwan S, Pardi DS, Tremaine WJ and Loftus EV, Jr.: Increased Risk of Acute Myocardial Infarction and Heart Failure in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol, 2018; 16: 1607-1615 e1601","DOI":"10.1016\/j.cgh.2018.04.031"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Bernstein CN, Wajda A and Blanchard JF: The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol, 2008; 6: 41-45","DOI":"10.1016\/j.cgh.2007.09.016"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM and Glynn RJ: Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J, 2018; 39: 3499-3507","DOI":"10.1093\/eurheartj\/ehy310"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ljung L, Rantapaa-Dahlqvist S, Jacobsson LT and Askling J: Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis, 2016; 75: 2087-2094","DOI":"10.1136\/annrheumdis-2015-208995"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R and Haraoui B: The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis, 2015; 74: 480-489","DOI":"10.1136\/annrheumdis-2014-206624"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, de Jong EM, Feist E, Jacobs A, Jobling R, Kemeny L, Maccarone M, Mrowietz U, Papp KA, Paul C, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN and Yawalkar N: European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol, 2015; 29: 2277-2294","DOI":"10.1111\/jdv.13354"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT and Anti TNFTACHFI: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation, 2003; 107: 3133-3140","DOI":"10.1161\/01.CIR.0000077913.60364.D2"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F and Fleming T: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation, 2004; 109: 1594-1602","DOI":"10.1161\/01.CIR.0000124490.27666.B2"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Wolfe F and Michaud K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med, 2004; 116: 305-311","DOI":"10.1016\/j.amjmed.2003.09.039"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S and Zink A: Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum, 2008; 58: 667-677","DOI":"10.1002\/art.23281"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, Wijbrandts CA, Tak PP, Lems WF, Dijkmans BA, van Vugt RM and Wolbink GJ: Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum, 2011; 63: 877-883","DOI":"10.1002\/art.30209"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Feng H, Zhao Y, Kuang W, Dai Y, Cen X and Qin F: Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: A meta-analysis of randomized, placebo-controlled trials. Front Pharmacol, 2023; 14: 1084614","DOI":"10.3389\/fphar.2023.1084614"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Chen YC, Huang YT, Yang CC, Lai EC, Liu CH, Hsu CK, Wong TW, Chao SC, Sheu HM and Lee CN: Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan. PLoS One, 2020; 15: e0244620","DOI":"10.1371\/journal.pone.0244620"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Wallis RS: Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis, 2008; 8: 601-611","DOI":"10.1016\/S1473-3099(08)70227-5"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Tran BN, Chan SL, Ng C, Shi J, Correia I, Radziejewski C and Matsudaira P: Higher order structures of Adalimumab, Infliximab and their complexes with TNFalpha revealed by electron microscopy. Protein Sci, 2017; 26: 2392-2398","DOI":"10.1002\/pro.3306"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Lim H, Lee SH, Lee HT, Lee JU, Son JY, Shin W and Heo YS: Structural Biology of the TNFalpha Antagonists Used in the Treatment of Rheumatoid Arthritis. Int J Mol Sci, 2018; 19:","DOI":"10.3390\/ijms19030768"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J and Sasso EH: Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol, 2009; 131: 308-316","DOI":"10.1016\/j.clim.2009.01.002"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Mitoma H, Horiuchi T, Tsukamoto H and Ueda N: Molecular mechanisms of action of anti-TNF-alpha agents - Comparison among therapeutic TNF-alpha antagonists. Cytokine, 2018; 101: 56-63","DOI":"10.1016\/j.cyto.2016.08.014"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Gjolberg TT, Frick R, Mester S, Foss S, Grevys A, Hoydahl LS, Jorstad OK, Schlothauer T, Sandlie I, Moe MC and Andersen JT: Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life. Commun Biol, 2022; 5: 832","DOI":"10.1038\/s42003-022-03787-x"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Carpentier I, Coornaert B and Beyaert R: Function and regulation of tumor necrosis factor receptor type 2. Curr Med Chem, 2004; 11: 2205-2212","DOI":"10.2174\/0929867043364694"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Hussain A, Tarahomi T, Singh L, Bollampally M, Heydari-Kamjani M and Kesselman MM: Cardiovascular Risk Associated With TNF Alpha Inhibitor Use in Patients With Rheumatoid Arthritis. Cureus, 2021; 13: e17938","DOI":"10.7759\/cureus.17938"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Ho CH, Silva AA, Tomita B, Weng HY and Ho IC: Differential impacts of TNFalpha inhibitors on the transcriptome of Th cells. Arthritis Res Ther, 2021; 23: 199","DOI":"10.1186\/s13075-021-02558-z"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Wojtal KA, Rogler G, Scharl M, Biedermann L, Frei P, Fried M, Weber A, Eloranta JJ, Kullak-Ublick GA and Vavricka SR: Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. PLoS One, 2012; 7: e43361","DOI":"10.1371\/journal.pone.0043361"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Nielsen CB, Nielsen C, Nybo M, Just SA and Vinholt PJ: The in vitro effect of antirheumatic drugs on platelet function. Platelets, 2020; 31: 248-257","DOI":"10.1080\/09537104.2019.1609665"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Arijs I, De Hertogh G, Machiels K, Van Steen K, Lemaire K, Schraenen A, Van Lommel L, Quintens R, Van Assche G, Vermeire S, Schuit F and Rutgeerts P: Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol, 2011; 106: 748-761","DOI":"10.1038\/ajg.2011.27"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Oldfield V and Plosker GL: Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs, 2009; 23: 125-135","DOI":"10.2165\/00063030-200923020-00005"},{"key":"51","unstructured":"51) Pereckova J, Martiniakova S, Payer J, Falk M, Killinger Z and Perecko T: Analysis of hematological parameters in rheumatoid arthritis patients receiving biological therapy: contribution to prevention of avoidable hematological complications. EXCLI J, 2022; 21: 580-594"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Hmamouchi I, Roux C, Paternotte S, Kolta S, Dougados M and Briot K: Early increase of abdominal adiposity in patients with spondyloarthritis receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol, 2014; 41: 1112-1117","DOI":"10.3899\/jrheum.131150"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Toussirot E, Mourot L, Dehecq B, Wendling D, Grandclement E, Dumoulin G and Cbt: TNFalpha blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. Eur J Nutr, 2014; 53: 951-961","DOI":"10.1007\/s00394-013-0599-2"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Onsun N, Akaslan TC, Sallahoglu K, Gulcan AS, Bulut H and Yabaci A: Effects of TNF inhibitors and an IL12\/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study. J Dermatolog Treat, 2022; 33: 1727-1732","DOI":"10.1080\/09546634.2021.1901845"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Veldhuijzen van Zanten J, Sandoo A, Metsios GS, Stavropoulos-Kalinoglou A, Ntoumanis N and Kitas GD: Comparison of the effects of exercise and anti-TNF treatment on cardiovascular health in rheumatoid arthritis: results from two controlled trials. Rheumatol Int, 2019; 39: 219-225","DOI":"10.1007\/s00296-018-4183-1"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Ait-Oufella H, Libby P and Tedgui A: Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk. Arterioscler Thromb Vasc Biol, 2019; 39: 1510-1519","DOI":"10.1161\/ATVBAHA.119.311998"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Akhmedov A, Crucet M, Simic B, Kraler S, Bonetti NR, Ospelt C, Distler O, Ciurea A, Liberale L, Jauhiainen M, Metso J, Miranda M, Cydecian R, Schwarz L, Fehr V, Zilinyi R, Amrollahi-Sharifabadi M, Ntari L, Karagianni N, Ruschitzka F, Laaksonen R, Vanhoutte PM, Kollias G, Camici GG and Luscher TF: TNFalpha induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNFalpha antibodies. Cardiovasc Res, 2022; 118: 254-266","DOI":"10.1093\/cvr\/cvab005"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/12\/31_64767\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T23:10:35Z","timestamp":1733526635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/12\/31_64767\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.64767","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]},"article-number":"64767"}}